Viatris (VTRS) Total Non-Current Liabilities (2019 - 2026)
Viatris (VTRS) posted quarterly Total Non-Current Liabilities of $20.1 billion for Q1 2026, down 4.22% year-over-year from $21.0 billion in Q1 2025, and down 1.82% quarter-over-quarter from $20.5 billion in Q4 2025.
Viatris (VTRS) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Viatris' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $20.1 billion for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 4.22% year-over-year to $20.1 billion; the TTM figure through Mar 2026 stood at $20.1 billion (down 4.22% YoY), while the FY2025 annual figure was $20.5 billion, down 2.19% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $20.1 billion, down from $20.5 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $31.1 billion in Q1 2022, with the low at $20.1 billion in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $25.7 billion (2023), against an average of $24.7 billion.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities gained 1.28% in 2024, then slipped 22.25% in 2025.
- Viatris' Total Non-Current Liabilities stood at $27.2 billion in 2022, then dropped by 5.49% to $25.7 billion in 2023, then declined by 18.58% to $20.9 billion in 2024, then fell by 2.19% to $20.5 billion in 2025, then fell by 1.82% to $20.1 billion in 2026.
- Business Quant data shows VTRS's Total Non-Current Liabilities at $20.1 billion in Q1 2026, $20.5 billion in Q4 2025, and $20.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 334.00 Mn |
| 10 | Alkermes | 8.09 Bn | 7.43 Bn | 397.90 Mn | 2.45 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.76 Bn |
| Mar 31, 2026 | 20.09 Bn |
| Dec 31, 2025 | 20.47 Bn |
| Sep 30, 2025 | 20.88 Bn |
| Jun 30, 2025 | 21.01 Bn |
| Mar 31, 2025 | 20.98 Bn |
| Dec 31, 2024 | 20.93 Bn |
| Sep 30, 2024 | 23.09 Bn |
| Jun 30, 2024 | 25.47 Bn |
| Mar 31, 2024 | 26.98 Bn |
| Dec 31, 2023 | 25.70 Bn |
| Sep 30, 2023 | 26.23 Bn |
| Jun 30, 2023 | 26.18 Bn |
| Mar 31, 2023 | 26.64 Bn |
| Dec 31, 2022 | 27.19 Bn |
| Sep 30, 2022 | 27.74 Bn |
| Jun 30, 2022 | 29.51 Bn |
| Mar 31, 2022 | 31.13 Bn |
| Sep 30, 2021 | 32.88 Bn |
| Jun 30, 2021 | 34.54 Bn |